"There are opportunities to take bioresorbable technology" to market in a less worksome context, suggesting that manufacturers spend some time "learning in the leg."

— Peter Fitzgerald, MD, of the Stanford University School of Medicine (Stanford, California) at the Transcatheter Cardiovascular Therapeutics meeting in San Francisco. "Drug-eluting balloon seen as no threat to eluting stents."